Antibody Drug Conjugates Market Opportunities: Investing in Future Therapies

Posted on 2024-10-17 by researchinsights in Internet & Online // 0 Comments

The global antibody drug conjugates market size was estimated at USD 11.29 billion in 2023 and is projected to grow at a CAGR of 9.2% from 2024 to 2030. This can be attributed to the presence of a robust R&D pipeline. This, coupled with the growing incidence of cancer and increased demand for low-toxicity & effective drugs, is expected to drive market growth. Some of the key Antibody Drug Conjugates (ADCs) currently available in the market are Kadcyla (Genentech/Roche), Adcetris (Seattle Genetics), Enhertu (AstraZeneca/Daiichi Sankyo), Besponsa (Pfizer), Mylotarg (Pfizer), and Polivy (Genentech/Roche). ADCs are a novel category of drugs composed of an antibody linked-via a chemical linker-to a cytotoxic drug.

Conventional chemotherapy is intended to eradicate fast-growing tumor cells. However, it can also damage healthy proliferating cells, which may produce undesirable effects. In contrast, ADC is designed to upsurge the efficacy of treatment and decrease systemic toxicity. In this market, the landscape is influenced by reimbursement policies, a crucial factor in developed economies. The production and research costs of ADC drugs are high compared to conventional treatments, such as monoclonal antibodies and chemotherapy. This results in a higher overall treatment cost, which poses a challenge for reimbursement coverage. For instance, a negative review was given by the National Centre for Pharmacoeconomics in Ireland in February 2020 for Roche’s Kadcyla (trastuzumab emtansine).

Gather more insights about the market drivers, restrains and growth of the Global Antibody Drug Conjugates Market

Detailed Segmentation:

Application Insights

The breast cancer segment dominated the market in 2023 with a revenue share of 47.76% owing to factors, such as a rise in incidence, promising pipeline products, and high adoption of Kadcyla. Trodelvy, Enhertu, and Kadcyla are the products approved for the treatment of breast cancer. The label expansion of Kadcyla to include patients with early breast cancer and the recent approval of Enhertu & Trodelvy are likely to drive segment growth. The blood cancer segment is expected to grow at a high CAGR from 2024 to 2030.

Product Insights

The Kadcyla segment held the largest revenue in the ADC space in 2023. The surge in breast cancer cases, coupled with heightened approvals for ADCs tailored for breast cancer treatment, propels the market’s upward trajectory. F. Hoffmann-La Roche Ltd. announced approval for Kadcyla in China’s rapidly expanding industry in January 2022 marking a pivotal development.

Target Insights

The HER2 or human epidermal growth factor receptor 2 target type segment held the largest market share in 2023. HER2 is a pivotal target. It plays a crucial role in breast cancer treatment, where overexpression is common. ADCs designed to target HER2 work by delivering potent drugs directly to cancer cells, minimizing damage to healthy cells, and enhancing therapeutic efficacy. Owing to all such factors, its adoption is high, which contributed to the segment’s industry dominance.

Technology Insights

The cleavable linker segment accounted for the largest revenue share of 72.43% in 2023. The ability of cleavable linkers to remain stable in the bloodstream for longer duration & release of cytotoxins from ADCs makes them the most popular used technology for an effective outcome of ADCs in cancer treatment. For instance, in 2020, Seagen’s & Takeda’s Adcetris was approved by NMPA for use in the treatment of relapsed Hodgkin’s lymphoma and relapsed systemic anaplastic large cell lymphoma sALCL in China. Such factors are expected to drive the cleavable linker segment growth.

Browse through Grand View Research’s Healthcare Industry Research Reports.

Aesthetic Lasers Market: The global aesthetic lasers market size was estimated at USD 1.60 billion in 2024 and is projected to grow at a CAGR of 16.9% from 2025 to 2030.

Vascular Closure Devices Market: The global vascular closure devices market size was valued at USD 1.56 billion in 2024 and is projected to grow at a CAGR of 5.7% from 2025 to 2030.

Regional Insights

The North America antibody drug conjugate market accounted for the largest revenue share of 52.54% in 2023. Increased awareness about ADCs among healthcare professionals and favorable reimbursement policies are driving market growth. North America is expected to witness significant growth over the forecast period owing to increased awareness about current treatment therapies, favorable reimbursement policies, significant R&D expenditure, and improved patient affordability. Some of the key players operating in this region are Seagen, Inc.; F. Hoffmann La-Roche Ltd.; Gilead Sciences Inc.; and Pfizer Inc.

Key Antibody Drug Conjugates Company Insights

Some of the key players operating in the market include Seagen, Inc., (previously Seattle Genetics, Inc.); Takeda Pharmaceutical Company Limited; AstraZeneca PLC, F. Hoffmann-La Roche Ltd.; Pfizer, Inc.; ImmunoGen, Inc.; Gilead Sciences, Inc. (acquired Immunomedics); and Daiichi Sankyo Company Ltd. Companies like F. Hoffmann-La Roche Ltd. hold key products, such as Kadcyla (ado-trastuzumab emtansine) and Polivy (polatuzumab vedotinpiiq). Kadcyla is a HER2-targeted antibody indicated for the treatment of Metastatic Breast Cancer (MBC) and Early Breast Cancer (EBC). Polivy is used in combination with bendamustine and rituximab for the treatment of adults with diffuse large B-cell lymphoma who have received at least 2 prior therapies.

Mersana Therapeutics, Inc., Heidelberg Pharma, and ADC Biotechnology are some of the emerging participants in the antibody drug conjugates market.

Key Antibody Drug Conjugates Companies:

The following are the leading companies in the antibody drug Conjugates market. These companies collectively hold the largest market share and dictate industry trends.

Matched content

Editor’s pick